ALS Svendsen

• Research type

  Research Study

• Full title

  Gene expression analysis of modified stem cells used as an experimental therapy in the treatment of amyotrophic lateral sclerosis.

• IRAS ID

  322360

• Contact name

  David Rowitch

• Contact email

  dhr25@cam.ac.uk

• Sponsor organisation

  University of Cambridge

• Duration of Study in the UK

  4 years, 9 months, 10 days

• Research summary

  A novel stem cell therapy treatment has been developed to treat amyotrophic lateral sclerosis (ALS); a neurodegenerative disease that damages the spinal cord. This treatment has seen success during clinical trials in America. We have partnered with Cedars-Sinai hospital in the US to examine migration of the modified stem cells used in the therapy in order to improve efficacy.

• REC name

  South Central - Hampshire B Research Ethics Committee

• REC reference

  23/SC/0034

• Date of REC Opinion

  10 Jan 2023

• REC opinion

  Favourable Opinion